1
Yale Endocrinology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 4th Floor Multispecialty Care Center
New Haven, CT 06511
1 of 4
- Yale EndocrinologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 4th Floor Multispecialty Care CenterNew Haven, CT 06511
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Diabetes CenterDana Clinic Building789 Howard Avenue, Ste 2nd FloorNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale Health Center55 Lock StreetNew Haven, CT 06511
Silvio Inzucchi, MD
Endocrinology, Diabetes Medicine & Management
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine
Biography
Silvio E. Inzucchi, MD, director of the Yale Medicine Diabetes Center, treats patients who suffer from diabetes as well as pituitary and adrenal disorders. “Endocrinology is fascinating, and we are usually able to help patients improve their quality of life through multidisciplinary care and academic approaches to endocrine conditions,” he says.
Dr. Inzucchi is a professor or medicine (endocrinology) at Yale School of Medicine and the clinical director of the section of endocrinology. In his research, Dr. Inzucchi, studies the cardiovascular effects of diabetes medications and glucose management in the hospital. Named a “top doctor” locally and nationally, Dr. Inzucchi has also received Yale’s David J. Leffell Prize for Clinical Excellence. The prize is given to individuals who demonstrate the highest level of clinical expertise, commitment to teaching and compassion for patients.
He says he has developed an effective personal approach to treating patients, carefully honed over 30 years at Yale. It includes being on top of the latest advances, but also responding to each patient’s individual needs. “I like to try to draw people out in terms of who they are, what’s important to them, their life experiences and their family. Such an approach resonates with patients because they don’t want to be seen as a patient, they want to be treated as a person,” he says.
Titles
- Professor of Medicine (Endocrinology)
Education & Training
- MDHarvard University (1985)
- BSFordham University (1981)
Additional Information
Board Certifications
- AB of Internal Medicine, Internal Medicine (1988)
Publications
- Butt J, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Koeber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Jhund P, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal 2024, 45: ehae666.1097. DOI: 10.1093/eurheartj/ehae666.1097.
- Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, Windsor S, Ilkayeva O, Muehlbauer M, Newgard C, Borlaug B, Kitzman D, Shah S, Margulies K, Husain M, Inzucchi S, McGuire D, Lanfear D, Javaheri A, Umpierrez G, Mentz R, Sharma K, Kosiborod M, Shah S. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circulation Heart Failure 2024, 17: e011980. PMID: 39421941, PMCID: PMC11634023, DOI: 10.1161/circheartfailure.124.011980.
- Pabon M, Vaduganathan M, Claggett B, Chatur S, Siqueira S, Marti‐Castellote P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Jhund P, McMurray J, Solomon S, Vardeny O. In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal Of Heart Failure 2024, 26: 2532-2540. PMID: 39300780, PMCID: PMC11683867, DOI: 10.1002/ejhf.3410.
- Butt J, Shen L, Inzucchi S, Docherty K, Jhund P, Martinez F, Sabatine M, Vaduganathan M, Solomon S, McMurray J, Committees and Investigators D. Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy A Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1946-1948. PMID: 39269393, DOI: 10.1016/j.jchf.2024.07.017.
- Abdin A, Kondo T, Böhm M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Desai A, Køber L, Sabatine M, Petersson M, Bachus E, Solomon S, McMurray J, Committees and Investigators O. Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 1952-1963. PMID: 39016033, DOI: 10.1002/ejhf.3350.
- Lassen M, Ostrominski J, Inzucchi S, Claggett B, Kulac I, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, Docherty K, McMurray J, Solomon S, Vaduganathan M. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial. European Journal Of Heart Failure 2024, 26: 1539-1548. PMID: 38745498, DOI: 10.1002/ejhf.3269.
- Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. European Journal Of Heart Failure 2024, 26: 1524-1538. PMID: 38700986, DOI: 10.1002/ejhf.3263.
- McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer R, Campbell R, Claggett B, Desai A, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Simpson J, Vaduganathan M, Jhund P, Solomon S, McMurray J. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 457-465. PMID: 38536153, PMCID: PMC10974691, DOI: 10.1001/jamacardio.2024.0284.
- Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.
- Pabón M, Wang X, Lam C, O'Meara E, Vaduganathan M, Claggett B, Foà A, Lu H, Langkilde A, De Boer R, Desai A, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Martinez F, Shah S, Petersson M, McMurray J, Solomon S, Vardeny O. Sex Differences in Heart Failure With Improved Ejection Fraction The DELIVER Trial. JACC Heart Failure 2024, 12: 1119-1122. PMID: 38661586, DOI: 10.1016/j.jchf.2024.03.011.
- Patel S, Kang Y, Im K, Neuen B, Anker S, Bhatt D, Butler J, Cherney D, Claggett B, Fletcher R, Herrington W, Inzucchi S, Jardine M, Mahaffey K, McGuire D, McMurray J, Neal B, Packer M, Perkovic V, Solomon S, Staplin N, Vaduganathan M, Wanner C, Wheeler D, Zannad F, Zhao Y, Heerspink H, Sabatine M, Wiviott S. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation 2024, 149: 1789-1801. PMID: 38583093, PMCID: PMC11149938, DOI: 10.1161/circulationaha.124.069568.
- Butt J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and Timing of Prior Heart Failure Hospitalization A Patient-Level Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1586-1599. PMID: 38573262, DOI: 10.1016/j.jchf.2024.01.018.
- Vaduganathan M, Claggett B, Kulac I, Johansen N, Reza N, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, McMurray J, Solomon S. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL. Journal Of The American College Of Cardiology 2024, 83: 320. DOI: 10.1016/s0735-1097(24)02310-6.
- Kondo T, Mogensen U, Talebi A, Gasparyan S, Campbell R, Docherty K, de Boer R, Inzucchi S, Køber L, Kosiborod M, Martinez F, Sabatine M, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. Journal Of The American College Of Cardiology 2024, 83: 1973-1986. PMID: 38537918, DOI: 10.1016/j.jacc.2024.03.385.
- Peikert A, Vaduganathan M, Claggett B, Kulac I, Foà A, Desai A, Jhund P, Carberry J, Lam C, Kosiborod M, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Køber L, Ponikowski P, Sabatine M, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 912-924. PMID: 38487939, DOI: 10.1002/ejhf.3184.
- Vardeny O, Desai A, Jhund P, Fang J, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mc Causland F, Petrie M, Vaduganathan M, McMurray J, Solomon S. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction. JAMA Cardiology 2024, 9: 283-289. PMID: 38265835, PMCID: PMC10809142, DOI: 10.1001/jamacardio.2023.5318.
- Green J, Everett B, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi S, Pokharel Y, Schade D, Scrymgeour A, Tan M, Utzschneider K, Mudaliar S, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la Torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Buse J, Kahn S, Larkin M, Tiktin M, Wexler D, Burch H, Bremer A, Lachin J, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge Jr E, Soni L, Steppel-Reznik J, Turchin A. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). Circulation 2024, 149: 993-1003. PMID: 38344820, PMCID: PMC10978227, DOI: 10.1161/circulationaha.123.066604.
- Levy J, Adeyina O, Robert S, Rimmer R, Inzucchi S, Rutherford H, Omay B. Increased Anxiety and Depression after Sellar Surgery: Is Oxytocin the Culprit?? Journal Of Neurological Surgery Part B Skull Base 2024, 85: s1-s398. DOI: 10.1055/s-0044-1780103.
- Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.
- Chang J, Javaheri A, Sauer A, Windsor S, Fu Z, Jones P, Margulies K, Lanfear D, Nassif M, Husain M, Inzucchi S, McGuire D, Pitt B, Scirica B, Kosiborod M. Cardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction. Journal Of Cardiac Failure 2024, 30: 236. DOI: 10.1016/j.cardfail.2023.10.284.
- Butt J, Jering K, DE Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Jhund P, Køber L, Kosiborod M, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Langkilde A, Bengtsson O, Petersson M, Sjöstrand M, Wilderäng U, Solomon S, McMurray J. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. Journal Of Cardiac Failure 2023, 30: 436-448. PMID: 38104937, DOI: 10.1016/j.cardfail.2023.08.027.
- Wang X, Lam C, Vaduganathan M, Kondo T, Yang M, Han Y, Pham V, Chiang C, Kitakaze M, Miao Z, Jhund P, Desai A, Inzucchi S, de Boer R, Martinez F, Kosiborod M, Hernandez A, Claggett B, Langkilde A, McMurray J, Solomon S. Effects of Dapagliflozin in Patients in Asia A Post Hoc Subgroup Analysis From the DELIVER Trial. JACC Asia 2023, 4: 108-118. PMID: 38371292, PMCID: PMC10866733, DOI: 10.1016/j.jacasi.2023.10.005.
- Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.
- Chatur S, Vaduganathan M, Claggett B, Desai A, Docherty K, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mcmurray J, Solomon S. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: ehad655.751. DOI: 10.1093/eurheartj/ehad655.751.
- Butt J, Lu H, Kondo T, Bachus E, De Boer R, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Shah S, Vaduganathan M, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial. European Heart Journal 2023, 44: ehad655.949. DOI: 10.1093/eurheartj/ehad655.949.
- Kondo T, Vaduganathan V, Hernandez A, Lam C, Inzucchi S, Martinez F, De Boer R, Kosiborod M, Desai A, Kober L, Ponikowski P, Sabatine M, Shah S, Solomon S, Mcmurray J. Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: ehad655.979. DOI: 10.1093/eurheartj/ehad655.979.
- Kondo T, Butt J, Curtain J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure 2023, 16: e010898. PMID: 37886880, DOI: 10.1161/circheartfailure.123.010898.
- Kondo T, Gasparyan S, Jhund P, Bengtsson O, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Langkilde A, Martinez F, Petersson M, Ponikowski P, Sabatine M, Shah S, Sjostrand M, Wilderang U, Vaduganathan M, Solomon S, McMurray J. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. NEJM Evidence 2023, 2: evidoa2300042. PMID: 38320525, DOI: 10.1056/evidoa2300042.
- Ostrominski J, Vaduganathan M, Selvaraj S, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation 2023, 148: 1945-1957. PMID: 37830208, DOI: 10.1161/circulationaha.123.065254.
- Bhatt A, Kosiborod M, Claggett B, Miao Z, Vaduganathan M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin‐Colet J, Drożdż J, Vardeny O, Merkely B, Lindholm D, Peterson M, Langkilde A, McMurray J, Solomon S. Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal Of Heart Failure 2023, 25: 2177-2188. PMID: 37771274, DOI: 10.1002/ejhf.3043.
- Peikert A, Bart B, Vaduganathan M, Claggett B, Kulac I, Kosiborod M, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vardeny O. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF The DELIVER Trial. JACC Heart Failure 2023, 12: 631-644. PMID: 37767674, DOI: 10.1016/j.jchf.2023.09.007.
- Butt J, Lu H, Kondo T, Bachus E, de Boer R, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Vaduganathan M, Solomon S, McMurray J. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. European Journal Of Heart Failure 2023, 25: 2078-2090. PMID: 37634087, DOI: 10.1002/ejhf.3000.
- Chatur S, Vaduganathan M, Claggett B, Cunningham J, Docherty K, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation 2023, 148: 1735-1745. PMID: 37632455, PMCID: PMC10664793, DOI: 10.1161/circulationaha.123.066506.
- Chatur S, Vaduganathan M, Claggett B, Mc Causland F, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Sabatine M, Kober L, Ponikowski P, Merkely B, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. Journal Of The American College Of Cardiology 2023, 82: 1854-1863. PMID: 37634707, DOI: 10.1016/j.jacc.2023.08.026.
- Kondo T, Wang X, Yang M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Langkilde A, Petersson M, Zaozerska N, Bachus E, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1014-1026. PMID: 37610398, DOI: 10.1016/j.jacc.2023.05.056.
- Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.
- Butt J, Docherty K, Kosiborod M, Inzucchi S, Køber L, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 11: 1411-1423. PMID: 37318419, DOI: 10.1016/j.jchf.2023.04.016.
- Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.
- Wojeck B, Inzucchi S, Neeland I, Mancuso J, Frederich R, Masiukiewicz U, Cater N, McGuire D, Cannon C, Yaggi H. Ertugliflozin and Incident Obstructive Sleep Apnea: An Analysis from the VERTIS CV Trial. Sleep Medicine 2022, 100: s249-s250. DOI: 10.1016/j.sleep.2022.05.671.
- Adamson C, Welsh P, Docherty K, de Boer R, Diez M, Drożdż J, Dukát A, Inzucchi S, Køber L, Kosiborod M, Ljungman C, Martinez F, Ponikowski P, Sabatine M, Morrow D, Lindholm D, Hammarstedt A, Boulton D, Greasley P, Langkilde A, Solomon S, Sattar N, McMurray J, Jhund P. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF. JACC Heart Failure 2022, 11: 291-304. PMID: 36592046, DOI: 10.1016/j.jchf.2022.09.004.
- Yang M, Butt J, Kondo T, Jering K, Docherty K, Jhund P, de Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Shah S, Vaduganathan M, Wilderäng U, Solomon S, McMurray J. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal Of Heart Failure 2022, 24: 2307-2319. PMID: 36342375, PMCID: PMC11497302, DOI: 10.1002/ejhf.2722.
- Yeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.833. DOI: 10.1093/eurheartj/ehac544.833.
- Kondo T, Jhund P, Abraham W, Rouleau J, Packer M, Desai A, Kober L, Solomon S, Zile M, Inzucchi S, Kosiborod M, Sabatine M, Ponikowski P, Martinez F, McMurray J. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model. European Heart Journal 2022, 43: ehac544.869. DOI: 10.1093/eurheartj/ehac544.869.
- Adamson C, Welsh P, Morrow D, Docherty K, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Sattar N, Jhund P, McMurray J. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.913. DOI: 10.1093/eurheartj/ehac544.913.
- Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.
- Myhre P, Vaduganathan M, Claggett B, Miao Z, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Lindholm D, Petersson M, Langkilde A, McMurray J, Solomon S. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Failure 2022, 10: 902-913. PMID: 36114137, DOI: 10.1016/j.jchf.2022.08.007.
- INZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED. Diabetes 2022, 71 DOI: 10.2337/db22-864-p.
- Ferreira J, Inzucchi S, Zinman B, Mattheus M, Meinicke T, Steubl D, Wanner C, Gotsch U. Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s62-s62. DOI: 10.1055/s-0042-1746380.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B, Wagner-Golbs A. Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s31-s32. DOI: 10.1055/s-0042-1746295.
- Anam A, Inzucchi S. Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. 2022, 527-553. DOI: 10.1007/978-3-030-92589-5_26.
- Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.
- Leasure A, Acosta J, Schwartz A, Forman R, Sharma R, de Havenon A, Falcone G, Inzucchi S, Kernan W, Sheth K. WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2022, 79: 1504. DOI: 10.1016/s0735-1097(22)02495-0.
- Hadjadj S, Kahl S, Ofstad A, Zinman B, Wanner C, Schüler E, Inzucchi S, Roden M. Effets de l’empagliflozine sur les marqueurs de la stéatose et de la fibrose hépatique et lien avec les résultats cardiorénaux dans l’étude EMPA-REG OUTCOME. Annales D Endocrinologie 2021, 82: 269-270. DOI: 10.1016/j.ando.2021.08.045.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.
- Wanner C, Nangaku M, Kraus B, Zinman B, Mattheus M, Ohneberg K, Hajmessaoud N, Zaoui P, Schmoor C, Inzucchi S. Médiateurs de l’effet du traitement par empagliflozine sur les résultats rénaux dans l’essai EMPA-REG OUTCOME. Néphrologie & Thérapeutique 2021, 17: 339. DOI: 10.1016/j.nephro.2021.07.233.
- KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.
- INZUCCHI S, WANNER C, FITCHETT D, ZINMAN B, ANKER S, MATTHEUS M, VEDIN O, HANTEL S, LUND S. 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME. Diabetes 2021, 70 DOI: 10.2337/db21-790-p.
- ATHONVARANGKUL D, BAK L, ZHENG C, D’AMBROSI J, SINER J, HONIDEN S, INZUCCHI S. 873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia. Diabetes 2021, 70 DOI: 10.2337/db21-873-p.
- Inzucchi, Zinman B, Wanner C, Fitchett D, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51-s52. DOI: 10.1055/s-0041-1727465.
- Kraus B, Weir, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, von Eynatten M, Zinman B, Inzucchi, Wanner C, Koitka-Webe A. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2021, 16: s52. DOI: 10.1055/s-0041-1727466.
- Fitchett D, Inzucchi, Zinman B, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51. DOI: 10.1055/s-0041-1727464.
- Vaduganathan M, Sattar N, Fitchett D, George J, Ofstad A, Verma S, Mattheus M, Wanner C, Inzucchi, Zinman B, Butler J. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s18-s19. DOI: 10.1055/s-0041-1727336.
- Wojeck B, Gossmann M, Zeidan A, Inzucchi S. Acute Myeloid Leukemia Leading to Central Diabetes Insipidus. Journal Of The Endocrine Society 2021, 5: a570-a571. PMCID: PMC8090637, DOI: 10.1210/jendso/bvab048.1163.
- Lupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome. Contemporary Endocrinology 2021, 9-25. DOI: 10.1007/978-3-030-67455-7_2.
- Hamilton A, Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, Mattheus M, Vedin O, Hantel S, Lund S. Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s220-s221. DOI: 10.1016/j.hlc.2021.06.278.
- Hamilton A, Inzucchi S, Wanner C, Fitchett D, Zinman B, Anker S, Mattheus M, Vedin O, Hantel S, Lund S. Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME. Heart Lung And Circulation 2021, 30: s221-s222. DOI: 10.1016/j.hlc.2021.06.281.
- Hong CS, Omuro A, An Y, Inzucchi S, Kohli AA, McGuone D, Vining EM, Omay SB, Erson-Omay E. Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. Neuro-Oncology Advances 2021, 3: vdab124. PMID: 34549183, PMCID: PMC8446933, DOI: 10.1093/noajnl/vdab124.
- Hamilton A, Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Association of Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Insights From the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s212-s213. DOI: 10.1016/j.hlc.2021.06.259.
- Dewan P, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0932. DOI: 10.1093/ehjci/ehaa946.0932.
- Kristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. European Heart Journal 2020, 41: ehaa946.0939. DOI: 10.1093/ehjci/ehaa946.0939.
- Kristensen S, Docherty K, Jhund P, Bengtsson O, Inzucchi S, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin Reduces the Risk of Hyperkalaemia in Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis from DAPA-HF. Journal Of The American Society Of Nephrology 2020, 31: 21-21. DOI: 10.1681/asn.20203110s121b.
- INZUCCHI S, DOCHERTY K, KOBER L, KOSIBOROD M, MARTINEZ F, PONIKOWSKI P, SABATINE M, SOLOMON S, BELOHLAVEK J, BÖHM M, CHIANG C, DE BOER R, DIEZ M, DUKAT A, LJUNGMAN C, VERMA S, DEMETS D, BENGTSSON O, LANGKILDE A, SJÖSTRAND M, JHUND P, MCMURRAY J. 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF. Diabetes 2020, 69 DOI: 10.2337/db20-271-or.
- VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.
- VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.
- PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4. Diabetes 2020, 69 DOI: 10.2337/db20-927-p.
- LIPSKA K, DOYLE M, CENGIZ E, DROZDOWICZ B, GILL T, MURPHY T, INZUCCHI S. 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM). Diabetes 2020, 69 DOI: 10.2337/db20-380-p.
- NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.
- INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.
- INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.
- BAK L, FANDEL T, BOZZO J, DEWITT M, CHEN P, PANDO R, FERRO L, KAPLAN R, HENDRICKSON K, AMPORT S, SUSSMAN L, INZUCCHI S. 23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center. Diabetes 2020, 69 DOI: 10.2337/db20-23-or.
- Athonvarangkul D, Hosier H, Wojeck B, Inzucchi S. SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma. Journal Of The Endocrine Society 2020, 4: sat-258. PMCID: PMC7207434, DOI: 10.1210/jendso/bvaa046.1057.
- Docherty K, Jackson A, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, Desai A, Diez M, Howlett J, Ljungman C, O'Meara E, Petrie M, Schou M, Pham V, McMurray J. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 656. DOI: 10.1016/s0735-1097(20)31283-3.
- Murari K, Gossman M, Mahajan A, Erson Z, Inzucchi S, Omay S. A Case of the Use of Genomic Signatures in the Diagnosis of Cushing Disease. Journal Of Neurological Surgery Part B Skull Base 2020, 81: s1-s272. DOI: 10.1055/s-0040-1702681.
- Kosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.
- Verma S, Qiuhe J, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2019, 35: s139. DOI: 10.1016/j.cjca.2019.07.554.
- Verma S, Böhm M, Brueckmann M, Fitchett D, George J, Inzucchi S, Marx N, Mattheus M, Ofstad A, Slawik J, Wanner C, Zinman B. HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDY. Canadian Journal Of Cardiology 2019, 35: s197. DOI: 10.1016/j.cjca.2019.07.619.
- McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.
- ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.
- INZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.
- INZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial. Diabetes 2019, 68 DOI: 10.2337/db19-248-or.
- Wanner C, Cooper M, Inzucchi S, Zinman B, Zwiener I, Eynatten M, Koitka-Weber A. Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c. Diabetologie Und Stoffwechsel 2019, 14: s80-s80. DOI: 10.1055/s-0039-1688342.
- Fitchett D, Inzucchi S, Sambevski S, Kaspers S, Pfarr E, George J, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE. Canadian Journal Of Cardiology 2018, 34: s80-s81. DOI: 10.1016/j.cjca.2018.07.288.
- Verma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. 124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial. Canadian Journal Of Diabetes 2018, 42: s43. DOI: 10.1016/j.jcjd.2018.08.129.
- Fitchett D, Inzucchi S, Cannon C, McGuire D, Johansen O, Sambevski S, Hehnke U, George J, Zinman B. P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline. European Heart Journal 2018, 39: ehy565.p1879. DOI: 10.1093/eurheartj/ehy565.p1879.
- McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, George J, Elsasser U, Woerle H, Lund S, Fitchett D. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. European Heart Journal 2018, 39: ehy566.p5334. DOI: 10.1093/eurheartj/ehy566.p5334.
- INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.
- FITCHETT D, SCIRICA B, INZUCCHI S, CANNON C, MCGUIRE D, JOHANSEN O, SAMBEVSKI S, HEHNKE U, GEORGE J, ZINMAN B. Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. Diabetes 2018, 67 DOI: 10.2337/db18-1123-p.
- WONG N, SONG Y, ARNOLD S, SPERLING L, CANNON C, INZUCCHI S, KOSIBOROD M. Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. Diabetes 2018, 67 DOI: 10.2337/db18-1487-p.
- RASOULI N, COHEN R, DEFRONZO R, INZUCCHI S, ISMAIL-BEIGI F, KAHN S, UTZSCHNEIDER K, LACHIN J, YOUNES N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort. Diabetes 2018, 67 DOI: 10.2337/db18-1822-p.
- WANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. Diabetes 2018, 67 DOI: 10.2337/db18-524-p.
- Ruggenenti P, Inzucchi S, Zinman B, Hantel S, Koitka-Weber A, von Eynatten M, Wanner C. SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL. Nephrology Dialysis Transplantation 2018, 33: i487-i487. DOI: 10.1093/ndt/gfy104.sp415.
- Inzucchi S, Zinman B, McGinniss J, Schnee J, George J, Fitchett D. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2017, 69: 1656. DOI: 10.1016/s0735-1097(17)35045-3.
- Inzucchi S, Matthews D. How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016, 471-492. DOI: 10.1002/9781118924853.ch33.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. 10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk. Canadian Journal Of Diabetes 2016, 40: s4-s5. DOI: 10.1016/j.jcjd.2016.08.013.
- Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2016, 32: s90-s91. DOI: 10.1016/j.cjca.2016.07.124.
- Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2016, 32: s175-s176. DOI: 10.1016/j.cjca.2016.07.272.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Canadian Journal Of Cardiology 2016, 32: s122-s123. DOI: 10.1016/j.cjca.2016.07.182.
- Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.
- Lleva RR, Thomas P, Bozzo JE, Hendrickson KC, Inzucchi SE. Using the Glucometrics Website to Benchmark ICU Glucose Control Before and After the NICE-SUGAR Study. Journal Of Diabetes Science And Technology 2014, 8: 918-922. PMID: 25013157, PMCID: PMC4455376, DOI: 10.1177/1932296814540871.
- Hoang QN, Pisani MA, Inzucchi S, Hu B, Honiden S. The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: A prospective observational study. Journal Of Critical Care 2014, 29: 1052-1056. PMID: 25092614, DOI: 10.1016/j.jcrc.2014.06.007.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 56: 680-680. DOI: 10.1007/s00125-012-2785-9.
- Matthews D, Inzucchi S, . Response to Comments on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379. Diabetes Care 2012, 35: e72-e73. PMCID: PMC3447838, DOI: 10.2337/dc12-1184.
- Matthews D, Inzucchi S, for the Position Statement Writing Group. ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]. Diabetologia 2012, 55: 2856-2857. PMID: 22854891, DOI: 10.1007/s00125-012-2669-z.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum 2012, 25: 154-171. DOI: 10.2337/diaspect.25.3.154.
- Inzucchi S, Rosenstock J, Umpierrez G. Diabetic Neuropathy. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 35a-35a. PMID: 22563114, DOI: 10.1210/jcem.97.5.zeg35a.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55: 1577-1596. PMID: 22526604, DOI: 10.1007/s00125-012-2534-0.
- Hage F, Wackers F, Bansal S, Chyun D, Young L, Inzucchi S, Iskandrian A. THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDY. Journal Of The American College Of Cardiology 2012, 59: e1162. DOI: 10.1016/s0735-1097(12)61163-2.
- Inzucchi S, Sherwin R. 236 Type 1 Diabetes Mellitus. 2012, e78-e94. DOI: 10.1016/b978-1-4377-1604-7.00561-3.
- Inzucchi S, Sherwin R. 237 Type 2 Diabetes Mellitus. 2012, 1489-1499. DOI: 10.1016/b978-1-4377-1604-7.00237-2.
- Tandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F. SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY. Journal Of The American College Of Cardiology 2011, 57: e745. DOI: 10.1016/s0735-1097(11)60745-6.
- Inzucchi S, Rosenstock J, Umpierrez G. Continuous Glucose Monitoring. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e1-e1. DOI: 10.1210/jcem.95.10.9998.
- Bansal S, Wackers F, Inzucchi S, Young L, Chyun D. CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIAL. Journal Of The American College Of Cardiology 2010, 55: a141.e1325. DOI: 10.1016/s0735-1097(10)61326-5.
- DeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting. 2009, 773-786. DOI: 10.1007/978-0-387-09841-8_47.
- Inzucchi S, Leiter L, Rosenstock J. Diabetes de Tipo 2 y las TZD (Tiazolidinedionas) Fritz 9.24.09. The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e1-e1. DOI: 10.1210/jcem.94.11.9987.
- Inzucchi S, Leiter L, Rosenstock J. Type 2 Diabetes and TZDs (Thiazolidinediones) Fritz 9.24.09. The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e2-e2. DOI: 10.1210/jcem.94.11.9988.
- Kosiborod M, Inzucchi S, Krumholz H, Masoudi F, Goyal A, Spertus J. Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?—Reply. JAMA Internal Medicine 2009, 169: 1633-1638. DOI: 10.1001/archinternmed.2009.327.
- Lipska K, Inzucchi, Kosiborod M, Krumholz H. Intensive glucose control and cardiovascular outcomes. The Lancet 2009, 374: 522-523. PMID: 19683633, DOI: 10.1016/s0140-6736(09)61479-3.
- Rosenstock J, Inzucchi S, Seufert J, Fleck P, Wilson C, Mekki Q. Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise. Canadian Journal Of Diabetes 2009, 33: 212. DOI: 10.1016/s1499-2671(09)33076-2.
- Lipska K, Inzucchi S. Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports 2008, 3: 42-50. DOI: 10.1007/s12170-009-0008-9.
- Hirsch I, Inzucchi S, Kirkman M. Standards of Medical Care in Diabetes—2008 Response to Dora, Kramer, and Canani. Diabetes Care 2008, 31: e45-e45. DOI: 10.2337/dc08-0285.
- Thomas P, Inzucchi S. An Internet Service Supporting Quality Assessment of Inpatient Glycemic Control. Journal Of Diabetes Science And Technology 2008, 2: 402-408. PMID: 19885204, PMCID: PMC2769729, DOI: 10.1177/193229680800200309.
- Inzucchi S, Rolla A, Umpierrez G. La diabetes y las nuevas insulinas. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e1-e1. DOI: 10.1210/jcem.92.3.9995.
- Inzucchi S, Rolla A, Umpierrez G. Diabetes and New Insulins. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e2-e2. DOI: 10.1210/jcem.92.3.9996.
- Holt E, Inzucchi S. Physiology and Pathophysiology of the Parathyroid Glands and Preoperative Evaluation. 2007, 235-243. DOI: 10.1007/978-3-540-68043-7_19.
- Inzucchi S. Chapter 26 Type 2 Diabetes Therapy: Choosing Oral Agents. 2006, 332-342. DOI: 10.1016/b978-1-4160-0273-4.50031-x.
- Bax J, Bonow R, Tschöepe D, Inzucchi S, Barrett E. Early detection of coronary heart disease in diabetic patients without symptoms of coronary artery disease: implications for expanded use of myocardial perfusion imaging. British Journal Of Diabetes 2005, 5: 283-288. DOI: 10.1177/14746514050050050801.
- Goldberg P, Roussel M, Inzucchi S. Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill Patients. Diabetes Spectrum 2005, 18: 188-191. DOI: 10.2337/diaspect.18.3.188.
- Kimmel B, Inzucchi S. Oral Agents for Type 2 Diabetes: An Update. Clinical Diabetes 2005, 23: 64-76. DOI: 10.2337/diaclin.23.2.64.
- Inzucchi S, Kinder B. Chapter 87 Endocrine Emergencies: Hypoglycemic and Hyperglycemic Crises. 2005, 789-799. DOI: 10.1016/b978-0-7216-0139-7.50091-0.
- Wackers F, Young L, Inzucchi S, Chyun D. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects. Diabetes Care 2005, 28: 232-233. DOI: 10.2337/diacare.28.1.232.
- Goldberg P, Inzucchi S. Selling Root Canals: Lessons Learned From Implementing a Hospital Insulin Infusion Protocol. Diabetes Spectrum 2005, 18: 28-33. DOI: 10.2337/diaspect.18.1.28.
- Inzucchi S, Young L, Chyun D, Wackers F. Screening for coronary artery disease in diabetic patients: The DIAD study. British Journal Of Diabetes 2004, 4: 317-319. DOI: 10.1177/14746514040040050501.
- Sudhakar S, Chyun D, Young L, Inzucchi S, Davey J, Wackers F. Abnormal heart rate response to adenosine infusion is associated with silent myocardial ischemia in asymptomatic patients with diabetes mellitus. Journal Of Nuclear Cardiology 2004, 11: s20. DOI: 10.1016/j.nuclcard.2004.06.064.
- Kosiborod M, Rathore S, Wang Y, Inzucchi S, Masoudi F, Havranek E, Foody J, Krumholz H. 885-6 Prognostic implications of admission hyperglycemia in elderly patients with acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 43: a241. DOI: 10.1016/s0735-1097(04)91025-x.
- Kernan W, Inzucchi S, Viscoli C. Insulin and Membrane Microviscosity of Erythrocytes as Risk Factors for Stroke. Stroke 2003, 34: e225-e226. PMID: 14631086, DOI: 10.1161/01.str.0000103353.56177.97.
- Inzucchi S, Sherwin R. Applying the Lessons of the DPP to Clinical Practice. Clinical Diabetes 2003, 21: 91-92. DOI: 10.2337/diaclin.21.2.91.
- Wackers F, Young L, Inzucchi S, Chyun D, Davey J. Detection of ischemia in asymptomatic diabetics: Preliminary results of the DIAD study. Journal Of The American College Of Cardiology 2003, 41: 409. DOI: 10.1016/s0735-1097(03)81197-x.
- Novella S, Inzucchi S, Goldstein J. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle & Nerve 2001, 24: 1229-1231. PMID: 11494278, DOI: 10.1002/mus.1137.
- Nakchbandi I, Inzucchi S, Wirth J. Primary Pulmonary Hypertension and Thyroid Disease. CHEST Journal 2000, 118: 1224-1225. DOI: 10.1016/s0012-3692(15)37735-7.
Locations
1
Yale Endocrinology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 4th Floor Multispecialty Care Center
New Haven, CT 06511
1 of 4
- Yale EndocrinologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 4th Floor Multispecialty Care CenterNew Haven, CT 06511
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Diabetes CenterDana Clinic Building789 Howard Avenue, Ste 2nd FloorNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale Health Center55 Lock StreetNew Haven, CT 06511
Biography
Silvio E. Inzucchi, MD, director of the Yale Medicine Diabetes Center, treats patients who suffer from diabetes as well as pituitary and adrenal disorders. “Endocrinology is fascinating, and we are usually able to help patients improve their quality of life through multidisciplinary care and academic approaches to endocrine conditions,” he says.
Dr. Inzucchi is a professor or medicine (endocrinology) at Yale School of Medicine and the clinical director of the section of endocrinology. In his research, Dr. Inzucchi, studies the cardiovascular effects of diabetes medications and glucose management in the hospital. Named a “top doctor” locally and nationally, Dr. Inzucchi has also received Yale’s David J. Leffell Prize for Clinical Excellence. The prize is given to individuals who demonstrate the highest level of clinical expertise, commitment to teaching and compassion for patients.
He says he has developed an effective personal approach to treating patients, carefully honed over 30 years at Yale. It includes being on top of the latest advances, but also responding to each patient’s individual needs. “I like to try to draw people out in terms of who they are, what’s important to them, their life experiences and their family. Such an approach resonates with patients because they don’t want to be seen as a patient, they want to be treated as a person,” he says.
Titles
- Professor of Medicine (Endocrinology)
Education & Training
- MDHarvard University (1985)
- BSFordham University (1981)
Additional Information
Board Certifications
- AB of Internal Medicine, Internal Medicine (1988)
Publications
- Butt J, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Koeber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Jhund P, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal 2024, 45: ehae666.1097. DOI: 10.1093/eurheartj/ehae666.1097.
- Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, Windsor S, Ilkayeva O, Muehlbauer M, Newgard C, Borlaug B, Kitzman D, Shah S, Margulies K, Husain M, Inzucchi S, McGuire D, Lanfear D, Javaheri A, Umpierrez G, Mentz R, Sharma K, Kosiborod M, Shah S. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circulation Heart Failure 2024, 17: e011980. PMID: 39421941, PMCID: PMC11634023, DOI: 10.1161/circheartfailure.124.011980.
- Pabon M, Vaduganathan M, Claggett B, Chatur S, Siqueira S, Marti‐Castellote P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Jhund P, McMurray J, Solomon S, Vardeny O. In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal Of Heart Failure 2024, 26: 2532-2540. PMID: 39300780, PMCID: PMC11683867, DOI: 10.1002/ejhf.3410.
- Butt J, Shen L, Inzucchi S, Docherty K, Jhund P, Martinez F, Sabatine M, Vaduganathan M, Solomon S, McMurray J, Committees and Investigators D. Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy A Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1946-1948. PMID: 39269393, DOI: 10.1016/j.jchf.2024.07.017.
- Abdin A, Kondo T, Böhm M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Desai A, Køber L, Sabatine M, Petersson M, Bachus E, Solomon S, McMurray J, Committees and Investigators O. Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 1952-1963. PMID: 39016033, DOI: 10.1002/ejhf.3350.
- Lassen M, Ostrominski J, Inzucchi S, Claggett B, Kulac I, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, Docherty K, McMurray J, Solomon S, Vaduganathan M. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial. European Journal Of Heart Failure 2024, 26: 1539-1548. PMID: 38745498, DOI: 10.1002/ejhf.3269.
- Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. European Journal Of Heart Failure 2024, 26: 1524-1538. PMID: 38700986, DOI: 10.1002/ejhf.3263.
- McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer R, Campbell R, Claggett B, Desai A, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Simpson J, Vaduganathan M, Jhund P, Solomon S, McMurray J. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 457-465. PMID: 38536153, PMCID: PMC10974691, DOI: 10.1001/jamacardio.2024.0284.
- Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.
- Pabón M, Wang X, Lam C, O'Meara E, Vaduganathan M, Claggett B, Foà A, Lu H, Langkilde A, De Boer R, Desai A, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Martinez F, Shah S, Petersson M, McMurray J, Solomon S, Vardeny O. Sex Differences in Heart Failure With Improved Ejection Fraction The DELIVER Trial. JACC Heart Failure 2024, 12: 1119-1122. PMID: 38661586, DOI: 10.1016/j.jchf.2024.03.011.
- Patel S, Kang Y, Im K, Neuen B, Anker S, Bhatt D, Butler J, Cherney D, Claggett B, Fletcher R, Herrington W, Inzucchi S, Jardine M, Mahaffey K, McGuire D, McMurray J, Neal B, Packer M, Perkovic V, Solomon S, Staplin N, Vaduganathan M, Wanner C, Wheeler D, Zannad F, Zhao Y, Heerspink H, Sabatine M, Wiviott S. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis. Circulation 2024, 149: 1789-1801. PMID: 38583093, PMCID: PMC11149938, DOI: 10.1161/circulationaha.124.069568.
- Butt J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and Timing of Prior Heart Failure Hospitalization A Patient-Level Meta-Analysis of DAPA-HF and DELIVER. JACC Heart Failure 2024, 12: 1586-1599. PMID: 38573262, DOI: 10.1016/j.jchf.2024.01.018.
- Vaduganathan M, Claggett B, Kulac I, Johansen N, Reza N, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, McMurray J, Solomon S. DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE ACROSS A RANGE OF LEFT VENTRICULAR HYPERTROPHY IN THE DELIVER TRIAL. Journal Of The American College Of Cardiology 2024, 83: 320. DOI: 10.1016/s0735-1097(24)02310-6.
- Kondo T, Mogensen U, Talebi A, Gasparyan S, Campbell R, Docherty K, de Boer R, Inzucchi S, Køber L, Kosiborod M, Martinez F, Sabatine M, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. Journal Of The American College Of Cardiology 2024, 83: 1973-1986. PMID: 38537918, DOI: 10.1016/j.jacc.2024.03.385.
- Peikert A, Vaduganathan M, Claggett B, Kulac I, Foà A, Desai A, Jhund P, Carberry J, Lam C, Kosiborod M, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Køber L, Ponikowski P, Sabatine M, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 912-924. PMID: 38487939, DOI: 10.1002/ejhf.3184.
- Vardeny O, Desai A, Jhund P, Fang J, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mc Causland F, Petrie M, Vaduganathan M, McMurray J, Solomon S. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction. JAMA Cardiology 2024, 9: 283-289. PMID: 38265835, PMCID: PMC10809142, DOI: 10.1001/jamacardio.2023.5318.
- Green J, Everett B, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi S, Pokharel Y, Schade D, Scrymgeour A, Tan M, Utzschneider K, Mudaliar S, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la Torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Buse J, Kahn S, Larkin M, Tiktin M, Wexler D, Burch H, Bremer A, Lachin J, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge Jr E, Soni L, Steppel-Reznik J, Turchin A. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). Circulation 2024, 149: 993-1003. PMID: 38344820, PMCID: PMC10978227, DOI: 10.1161/circulationaha.123.066604.
- Levy J, Adeyina O, Robert S, Rimmer R, Inzucchi S, Rutherford H, Omay B. Increased Anxiety and Depression after Sellar Surgery: Is Oxytocin the Culprit?? Journal Of Neurological Surgery Part B Skull Base 2024, 85: s1-s398. DOI: 10.1055/s-0044-1780103.
- Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, Vardeny O, Fang J, de Boer R, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 144-152. PMID: 37952176, PMCID: PMC10641768, DOI: 10.1001/jamacardio.2023.4664.
- Chang J, Javaheri A, Sauer A, Windsor S, Fu Z, Jones P, Margulies K, Lanfear D, Nassif M, Husain M, Inzucchi S, McGuire D, Pitt B, Scirica B, Kosiborod M. Cardiac And Kidney Benefits Of Dapagliflozin Are Associated With ApoM Levels In Patients With Heart Failure With Reduced Ejection Fraction. Journal Of Cardiac Failure 2024, 30: 236. DOI: 10.1016/j.cardfail.2023.10.284.
- Butt J, Jering K, DE Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Jhund P, Køber L, Kosiborod M, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Langkilde A, Bengtsson O, Petersson M, Sjöstrand M, Wilderäng U, Solomon S, McMurray J. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. Journal Of Cardiac Failure 2023, 30: 436-448. PMID: 38104937, DOI: 10.1016/j.cardfail.2023.08.027.
- Wang X, Lam C, Vaduganathan M, Kondo T, Yang M, Han Y, Pham V, Chiang C, Kitakaze M, Miao Z, Jhund P, Desai A, Inzucchi S, de Boer R, Martinez F, Kosiborod M, Hernandez A, Claggett B, Langkilde A, McMurray J, Solomon S. Effects of Dapagliflozin in Patients in Asia A Post Hoc Subgroup Analysis From the DELIVER Trial. JACC Asia 2023, 4: 108-118. PMID: 38371292, PMCID: PMC10866733, DOI: 10.1016/j.jacasi.2023.10.005.
- Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.
- Chatur S, Vaduganathan M, Claggett B, Desai A, Docherty K, Jhund P, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Mcmurray J, Solomon S. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial. European Heart Journal 2023, 44: ehad655.751. DOI: 10.1093/eurheartj/ehad655.751.
- Butt J, Lu H, Kondo T, Bachus E, De Boer R, Hernandez A, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Shah S, Vaduganathan M, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial. European Heart Journal 2023, 44: ehad655.949. DOI: 10.1093/eurheartj/ehad655.949.
- Kondo T, Vaduganathan V, Hernandez A, Lam C, Inzucchi S, Martinez F, De Boer R, Kosiborod M, Desai A, Kober L, Ponikowski P, Sabatine M, Shah S, Solomon S, Mcmurray J. Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: ehad655.979. DOI: 10.1093/eurheartj/ehad655.979.
- Kondo T, Butt J, Curtain J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure 2023, 16: e010898. PMID: 37886880, DOI: 10.1161/circheartfailure.123.010898.
- Kondo T, Gasparyan S, Jhund P, Bengtsson O, Claggett B, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Køber L, Lam C, Langkilde A, Martinez F, Petersson M, Ponikowski P, Sabatine M, Shah S, Sjostrand M, Wilderang U, Vaduganathan M, Solomon S, McMurray J. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. NEJM Evidence 2023, 2: evidoa2300042. PMID: 38320525, DOI: 10.1056/evidoa2300042.
- Ostrominski J, Vaduganathan M, Selvaraj S, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation 2023, 148: 1945-1957. PMID: 37830208, DOI: 10.1161/circulationaha.123.065254.
- Bhatt A, Kosiborod M, Claggett B, Miao Z, Vaduganathan M, Lam C, Hernandez A, Martinez F, Inzucchi S, Shah S, de Boer R, Jhund P, Desai A, Fang J, Han Y, Comin‐Colet J, Drożdż J, Vardeny O, Merkely B, Lindholm D, Peterson M, Langkilde A, McMurray J, Solomon S. Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial. European Journal Of Heart Failure 2023, 25: 2177-2188. PMID: 37771274, DOI: 10.1002/ejhf.3043.
- Peikert A, Bart B, Vaduganathan M, Claggett B, Kulac I, Kosiborod M, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vardeny O. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF The DELIVER Trial. JACC Heart Failure 2023, 12: 631-644. PMID: 37767674, DOI: 10.1016/j.jchf.2023.09.007.
- Butt J, Lu H, Kondo T, Bachus E, de Boer R, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Vaduganathan M, Solomon S, McMurray J. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. European Journal Of Heart Failure 2023, 25: 2078-2090. PMID: 37634087, DOI: 10.1002/ejhf.3000.
- Chatur S, Vaduganathan M, Claggett B, Cunningham J, Docherty K, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial. Circulation 2023, 148: 1735-1745. PMID: 37632455, PMCID: PMC10664793, DOI: 10.1161/circulationaha.123.066506.
- Chatur S, Vaduganathan M, Claggett B, Mc Causland F, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Sabatine M, Kober L, Ponikowski P, Merkely B, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. Journal Of The American College Of Cardiology 2023, 82: 1854-1863. PMID: 37634707, DOI: 10.1016/j.jacc.2023.08.026.
- Kondo T, Wang X, Yang M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Langkilde A, Petersson M, Zaozerska N, Bachus E, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1014-1026. PMID: 37610398, DOI: 10.1016/j.jacc.2023.05.056.
- Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.
- Butt J, Docherty K, Kosiborod M, Inzucchi S, Køber L, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 11: 1411-1423. PMID: 37318419, DOI: 10.1016/j.jchf.2023.04.016.
- Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.
- Wojeck B, Inzucchi S, Neeland I, Mancuso J, Frederich R, Masiukiewicz U, Cater N, McGuire D, Cannon C, Yaggi H. Ertugliflozin and Incident Obstructive Sleep Apnea: An Analysis from the VERTIS CV Trial. Sleep Medicine 2022, 100: s249-s250. DOI: 10.1016/j.sleep.2022.05.671.
- Adamson C, Welsh P, Docherty K, de Boer R, Diez M, Drożdż J, Dukát A, Inzucchi S, Køber L, Kosiborod M, Ljungman C, Martinez F, Ponikowski P, Sabatine M, Morrow D, Lindholm D, Hammarstedt A, Boulton D, Greasley P, Langkilde A, Solomon S, Sattar N, McMurray J, Jhund P. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF. JACC Heart Failure 2022, 11: 291-304. PMID: 36592046, DOI: 10.1016/j.jchf.2022.09.004.
- Yang M, Butt J, Kondo T, Jering K, Docherty K, Jhund P, de Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Shah S, Vaduganathan M, Wilderäng U, Solomon S, McMurray J. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal Of Heart Failure 2022, 24: 2307-2319. PMID: 36342375, PMCID: PMC11497302, DOI: 10.1002/ejhf.2722.
- Yeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.833. DOI: 10.1093/eurheartj/ehac544.833.
- Kondo T, Jhund P, Abraham W, Rouleau J, Packer M, Desai A, Kober L, Solomon S, Zile M, Inzucchi S, Kosiborod M, Sabatine M, Ponikowski P, Martinez F, McMurray J. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model. European Heart Journal 2022, 43: ehac544.869. DOI: 10.1093/eurheartj/ehac544.869.
- Adamson C, Welsh P, Morrow D, Docherty K, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Sattar N, Jhund P, McMurray J. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.913. DOI: 10.1093/eurheartj/ehac544.913.
- Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.
- Myhre P, Vaduganathan M, Claggett B, Miao Z, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Lindholm D, Petersson M, Langkilde A, McMurray J, Solomon S. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Failure 2022, 10: 902-913. PMID: 36114137, DOI: 10.1016/j.jchf.2022.08.007.
- INZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED. Diabetes 2022, 71 DOI: 10.2337/db22-864-p.
- Ferreira J, Inzucchi S, Zinman B, Mattheus M, Meinicke T, Steubl D, Wanner C, Gotsch U. Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s62-s62. DOI: 10.1055/s-0042-1746380.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B, Wagner-Golbs A. Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2022, 17: s31-s32. DOI: 10.1055/s-0042-1746295.
- Anam A, Inzucchi S. Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. 2022, 527-553. DOI: 10.1007/978-3-030-92589-5_26.
- Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.
- Leasure A, Acosta J, Schwartz A, Forman R, Sharma R, de Havenon A, Falcone G, Inzucchi S, Kernan W, Sheth K. WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION. Journal Of The American College Of Cardiology 2022, 79: 1504. DOI: 10.1016/s0735-1097(22)02495-0.
- Hadjadj S, Kahl S, Ofstad A, Zinman B, Wanner C, Schüler E, Inzucchi S, Roden M. Effets de l’empagliflozine sur les marqueurs de la stéatose et de la fibrose hépatique et lien avec les résultats cardiorénaux dans l’étude EMPA-REG OUTCOME. Annales D Endocrinologie 2021, 82: 269-270. DOI: 10.1016/j.ando.2021.08.045.
- Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.
- Wanner C, Nangaku M, Kraus B, Zinman B, Mattheus M, Ohneberg K, Hajmessaoud N, Zaoui P, Schmoor C, Inzucchi S. Médiateurs de l’effet du traitement par empagliflozine sur les résultats rénaux dans l’essai EMPA-REG OUTCOME. Néphrologie & Thérapeutique 2021, 17: 339. DOI: 10.1016/j.nephro.2021.07.233.
- KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.
- INZUCCHI S, WANNER C, FITCHETT D, ZINMAN B, ANKER S, MATTHEUS M, VEDIN O, HANTEL S, LUND S. 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME. Diabetes 2021, 70 DOI: 10.2337/db21-790-p.
- ATHONVARANGKUL D, BAK L, ZHENG C, D’AMBROSI J, SINER J, HONIDEN S, INZUCCHI S. 873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia. Diabetes 2021, 70 DOI: 10.2337/db21-873-p.
- Inzucchi, Zinman B, Wanner C, Fitchett D, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51-s52. DOI: 10.1055/s-0041-1727465.
- Kraus B, Weir, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, von Eynatten M, Zinman B, Inzucchi, Wanner C, Koitka-Webe A. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2021, 16: s52. DOI: 10.1055/s-0041-1727466.
- Fitchett D, Inzucchi, Zinman B, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51. DOI: 10.1055/s-0041-1727464.
- Vaduganathan M, Sattar N, Fitchett D, George J, Ofstad A, Verma S, Mattheus M, Wanner C, Inzucchi, Zinman B, Butler J. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s18-s19. DOI: 10.1055/s-0041-1727336.
- Wojeck B, Gossmann M, Zeidan A, Inzucchi S. Acute Myeloid Leukemia Leading to Central Diabetes Insipidus. Journal Of The Endocrine Society 2021, 5: a570-a571. PMCID: PMC8090637, DOI: 10.1210/jendso/bvab048.1163.
- Lupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome. Contemporary Endocrinology 2021, 9-25. DOI: 10.1007/978-3-030-67455-7_2.
- Hamilton A, Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, Mattheus M, Vedin O, Hantel S, Lund S. Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s220-s221. DOI: 10.1016/j.hlc.2021.06.278.
- Hamilton A, Inzucchi S, Wanner C, Fitchett D, Zinman B, Anker S, Mattheus M, Vedin O, Hantel S, Lund S. Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME. Heart Lung And Circulation 2021, 30: s221-s222. DOI: 10.1016/j.hlc.2021.06.281.
- Hong CS, Omuro A, An Y, Inzucchi S, Kohli AA, McGuone D, Vining EM, Omay SB, Erson-Omay E. Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. Neuro-Oncology Advances 2021, 3: vdab124. PMID: 34549183, PMCID: PMC8446933, DOI: 10.1093/noajnl/vdab124.
- Hamilton A, Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Association of Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Insights From the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s212-s213. DOI: 10.1016/j.hlc.2021.06.259.
- Dewan P, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0932. DOI: 10.1093/ehjci/ehaa946.0932.
- Kristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF. European Heart Journal 2020, 41: ehaa946.0939. DOI: 10.1093/ehjci/ehaa946.0939.
- Kristensen S, Docherty K, Jhund P, Bengtsson O, Inzucchi S, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin Reduces the Risk of Hyperkalaemia in Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis from DAPA-HF. Journal Of The American Society Of Nephrology 2020, 31: 21-21. DOI: 10.1681/asn.20203110s121b.
- INZUCCHI S, DOCHERTY K, KOBER L, KOSIBOROD M, MARTINEZ F, PONIKOWSKI P, SABATINE M, SOLOMON S, BELOHLAVEK J, BÖHM M, CHIANG C, DE BOER R, DIEZ M, DUKAT A, LJUNGMAN C, VERMA S, DEMETS D, BENGTSSON O, LANGKILDE A, SJÖSTRAND M, JHUND P, MCMURRAY J. 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF. Diabetes 2020, 69 DOI: 10.2337/db20-271-or.
- VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.
- VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.
- PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4. Diabetes 2020, 69 DOI: 10.2337/db20-927-p.
- LIPSKA K, DOYLE M, CENGIZ E, DROZDOWICZ B, GILL T, MURPHY T, INZUCCHI S. 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM). Diabetes 2020, 69 DOI: 10.2337/db20-380-p.
- NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.
- INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.
- INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.
- BAK L, FANDEL T, BOZZO J, DEWITT M, CHEN P, PANDO R, FERRO L, KAPLAN R, HENDRICKSON K, AMPORT S, SUSSMAN L, INZUCCHI S. 23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center. Diabetes 2020, 69 DOI: 10.2337/db20-23-or.
- Athonvarangkul D, Hosier H, Wojeck B, Inzucchi S. SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma. Journal Of The Endocrine Society 2020, 4: sat-258. PMCID: PMC7207434, DOI: 10.1210/jendso/bvaa046.1057.
- Docherty K, Jackson A, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, Desai A, Diez M, Howlett J, Ljungman C, O'Meara E, Petrie M, Schou M, Pham V, McMurray J. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 656. DOI: 10.1016/s0735-1097(20)31283-3.
- Murari K, Gossman M, Mahajan A, Erson Z, Inzucchi S, Omay S. A Case of the Use of Genomic Signatures in the Diagnosis of Cushing Disease. Journal Of Neurological Surgery Part B Skull Base 2020, 81: s1-s272. DOI: 10.1055/s-0040-1702681.
- Kosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.
- Verma S, Qiuhe J, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2019, 35: s139. DOI: 10.1016/j.cjca.2019.07.554.
- Verma S, Böhm M, Brueckmann M, Fitchett D, George J, Inzucchi S, Marx N, Mattheus M, Ofstad A, Slawik J, Wanner C, Zinman B. HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDY. Canadian Journal Of Cardiology 2019, 35: s197. DOI: 10.1016/j.cjca.2019.07.619.
- McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.
- ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.
- INZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.
- INZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial. Diabetes 2019, 68 DOI: 10.2337/db19-248-or.
- Wanner C, Cooper M, Inzucchi S, Zinman B, Zwiener I, Eynatten M, Koitka-Weber A. Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c. Diabetologie Und Stoffwechsel 2019, 14: s80-s80. DOI: 10.1055/s-0039-1688342.
- Fitchett D, Inzucchi S, Sambevski S, Kaspers S, Pfarr E, George J, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE. Canadian Journal Of Cardiology 2018, 34: s80-s81. DOI: 10.1016/j.cjca.2018.07.288.
- Verma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. 124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial. Canadian Journal Of Diabetes 2018, 42: s43. DOI: 10.1016/j.jcjd.2018.08.129.
- Fitchett D, Inzucchi S, Cannon C, McGuire D, Johansen O, Sambevski S, Hehnke U, George J, Zinman B. P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline. European Heart Journal 2018, 39: ehy565.p1879. DOI: 10.1093/eurheartj/ehy565.p1879.
- McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, George J, Elsasser U, Woerle H, Lund S, Fitchett D. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. European Heart Journal 2018, 39: ehy566.p5334. DOI: 10.1093/eurheartj/ehy566.p5334.
- INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.
- FITCHETT D, SCIRICA B, INZUCCHI S, CANNON C, MCGUIRE D, JOHANSEN O, SAMBEVSKI S, HEHNKE U, GEORGE J, ZINMAN B. Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. Diabetes 2018, 67 DOI: 10.2337/db18-1123-p.
- WONG N, SONG Y, ARNOLD S, SPERLING L, CANNON C, INZUCCHI S, KOSIBOROD M. Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. Diabetes 2018, 67 DOI: 10.2337/db18-1487-p.
- RASOULI N, COHEN R, DEFRONZO R, INZUCCHI S, ISMAIL-BEIGI F, KAHN S, UTZSCHNEIDER K, LACHIN J, YOUNES N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort. Diabetes 2018, 67 DOI: 10.2337/db18-1822-p.
- WANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. Diabetes 2018, 67 DOI: 10.2337/db18-524-p.
- Ruggenenti P, Inzucchi S, Zinman B, Hantel S, Koitka-Weber A, von Eynatten M, Wanner C. SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL. Nephrology Dialysis Transplantation 2018, 33: i487-i487. DOI: 10.1093/ndt/gfy104.sp415.
- Inzucchi S, Zinman B, McGinniss J, Schnee J, George J, Fitchett D. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2017, 69: 1656. DOI: 10.1016/s0735-1097(17)35045-3.
- Inzucchi S, Matthews D. How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016, 471-492. DOI: 10.1002/9781118924853.ch33.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. 10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk. Canadian Journal Of Diabetes 2016, 40: s4-s5. DOI: 10.1016/j.jcjd.2016.08.013.
- Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2016, 32: s90-s91. DOI: 10.1016/j.cjca.2016.07.124.
- Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2016, 32: s175-s176. DOI: 10.1016/j.cjca.2016.07.272.
- Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Canadian Journal Of Cardiology 2016, 32: s122-s123. DOI: 10.1016/j.cjca.2016.07.182.
- Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.
- Lleva RR, Thomas P, Bozzo JE, Hendrickson KC, Inzucchi SE. Using the Glucometrics Website to Benchmark ICU Glucose Control Before and After the NICE-SUGAR Study. Journal Of Diabetes Science And Technology 2014, 8: 918-922. PMID: 25013157, PMCID: PMC4455376, DOI: 10.1177/1932296814540871.
- Hoang QN, Pisani MA, Inzucchi S, Hu B, Honiden S. The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: A prospective observational study. Journal Of Critical Care 2014, 29: 1052-1056. PMID: 25092614, DOI: 10.1016/j.jcrc.2014.06.007.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 56: 680-680. DOI: 10.1007/s00125-012-2785-9.
- Matthews D, Inzucchi S, . Response to Comments on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379. Diabetes Care 2012, 35: e72-e73. PMCID: PMC3447838, DOI: 10.2337/dc12-1184.
- Matthews D, Inzucchi S, for the Position Statement Writing Group. ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS [letter], Scheen AJ [letter] and Ceriello A, Gallo M, Gentile S et al [letter]. Diabetologia 2012, 55: 2856-2857. PMID: 22854891, DOI: 10.1007/s00125-012-2669-z.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum 2012, 25: 154-171. DOI: 10.2337/diaspect.25.3.154.
- Inzucchi S, Rosenstock J, Umpierrez G. Diabetic Neuropathy. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 35a-35a. PMID: 22563114, DOI: 10.1210/jcem.97.5.zeg35a.
- Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55: 1577-1596. PMID: 22526604, DOI: 10.1007/s00125-012-2534-0.
- Hage F, Wackers F, Bansal S, Chyun D, Young L, Inzucchi S, Iskandrian A. THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDY. Journal Of The American College Of Cardiology 2012, 59: e1162. DOI: 10.1016/s0735-1097(12)61163-2.
- Inzucchi S, Sherwin R. 236 Type 1 Diabetes Mellitus. 2012, e78-e94. DOI: 10.1016/b978-1-4377-1604-7.00561-3.
- Inzucchi S, Sherwin R. 237 Type 2 Diabetes Mellitus. 2012, 1489-1499. DOI: 10.1016/b978-1-4377-1604-7.00237-2.
- Tandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F. SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY. Journal Of The American College Of Cardiology 2011, 57: e745. DOI: 10.1016/s0735-1097(11)60745-6.
- Inzucchi S, Rosenstock J, Umpierrez G. Continuous Glucose Monitoring. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e1-e1. DOI: 10.1210/jcem.95.10.9998.
- Bansal S, Wackers F, Inzucchi S, Young L, Chyun D. CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIAL. Journal Of The American College Of Cardiology 2010, 55: a141.e1325. DOI: 10.1016/s0735-1097(10)61326-5.
- DeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting. 2009, 773-786. DOI: 10.1007/978-0-387-09841-8_47.
- Inzucchi S, Leiter L, Rosenstock J. Diabetes de Tipo 2 y las TZD (Tiazolidinedionas) Fritz 9.24.09. The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e1-e1. DOI: 10.1210/jcem.94.11.9987.
- Inzucchi S, Leiter L, Rosenstock J. Type 2 Diabetes and TZDs (Thiazolidinediones) Fritz 9.24.09. The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e2-e2. DOI: 10.1210/jcem.94.11.9988.
- Kosiborod M, Inzucchi S, Krumholz H, Masoudi F, Goyal A, Spertus J. Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?—Reply. JAMA Internal Medicine 2009, 169: 1633-1638. DOI: 10.1001/archinternmed.2009.327.
- Lipska K, Inzucchi, Kosiborod M, Krumholz H. Intensive glucose control and cardiovascular outcomes. The Lancet 2009, 374: 522-523. PMID: 19683633, DOI: 10.1016/s0140-6736(09)61479-3.
- Rosenstock J, Inzucchi S, Seufert J, Fleck P, Wilson C, Mekki Q. Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise. Canadian Journal Of Diabetes 2009, 33: 212. DOI: 10.1016/s1499-2671(09)33076-2.
- Lipska K, Inzucchi S. Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports 2008, 3: 42-50. DOI: 10.1007/s12170-009-0008-9.
- Hirsch I, Inzucchi S, Kirkman M. Standards of Medical Care in Diabetes—2008 Response to Dora, Kramer, and Canani. Diabetes Care 2008, 31: e45-e45. DOI: 10.2337/dc08-0285.
- Thomas P, Inzucchi S. An Internet Service Supporting Quality Assessment of Inpatient Glycemic Control. Journal Of Diabetes Science And Technology 2008, 2: 402-408. PMID: 19885204, PMCID: PMC2769729, DOI: 10.1177/193229680800200309.
- Inzucchi S, Rolla A, Umpierrez G. La diabetes y las nuevas insulinas. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e1-e1. DOI: 10.1210/jcem.92.3.9995.
- Inzucchi S, Rolla A, Umpierrez G. Diabetes and New Insulins. The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e2-e2. DOI: 10.1210/jcem.92.3.9996.
- Holt E, Inzucchi S. Physiology and Pathophysiology of the Parathyroid Glands and Preoperative Evaluation. 2007, 235-243. DOI: 10.1007/978-3-540-68043-7_19.
- Inzucchi S. Chapter 26 Type 2 Diabetes Therapy: Choosing Oral Agents. 2006, 332-342. DOI: 10.1016/b978-1-4160-0273-4.50031-x.
- Bax J, Bonow R, Tschöepe D, Inzucchi S, Barrett E. Early detection of coronary heart disease in diabetic patients without symptoms of coronary artery disease: implications for expanded use of myocardial perfusion imaging. British Journal Of Diabetes 2005, 5: 283-288. DOI: 10.1177/14746514050050050801.
- Goldberg P, Roussel M, Inzucchi S. Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill Patients. Diabetes Spectrum 2005, 18: 188-191. DOI: 10.2337/diaspect.18.3.188.
- Kimmel B, Inzucchi S. Oral Agents for Type 2 Diabetes: An Update. Clinical Diabetes 2005, 23: 64-76. DOI: 10.2337/diaclin.23.2.64.
- Inzucchi S, Kinder B. Chapter 87 Endocrine Emergencies: Hypoglycemic and Hyperglycemic Crises. 2005, 789-799. DOI: 10.1016/b978-0-7216-0139-7.50091-0.
- Wackers F, Young L, Inzucchi S, Chyun D. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects. Diabetes Care 2005, 28: 232-233. DOI: 10.2337/diacare.28.1.232.
- Goldberg P, Inzucchi S. Selling Root Canals: Lessons Learned From Implementing a Hospital Insulin Infusion Protocol. Diabetes Spectrum 2005, 18: 28-33. DOI: 10.2337/diaspect.18.1.28.
- Inzucchi S, Young L, Chyun D, Wackers F. Screening for coronary artery disease in diabetic patients: The DIAD study. British Journal Of Diabetes 2004, 4: 317-319. DOI: 10.1177/14746514040040050501.
- Sudhakar S, Chyun D, Young L, Inzucchi S, Davey J, Wackers F. Abnormal heart rate response to adenosine infusion is associated with silent myocardial ischemia in asymptomatic patients with diabetes mellitus. Journal Of Nuclear Cardiology 2004, 11: s20. DOI: 10.1016/j.nuclcard.2004.06.064.
- Kosiborod M, Rathore S, Wang Y, Inzucchi S, Masoudi F, Havranek E, Foody J, Krumholz H. 885-6 Prognostic implications of admission hyperglycemia in elderly patients with acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 43: a241. DOI: 10.1016/s0735-1097(04)91025-x.
- Kernan W, Inzucchi S, Viscoli C. Insulin and Membrane Microviscosity of Erythrocytes as Risk Factors for Stroke. Stroke 2003, 34: e225-e226. PMID: 14631086, DOI: 10.1161/01.str.0000103353.56177.97.
- Inzucchi S, Sherwin R. Applying the Lessons of the DPP to Clinical Practice. Clinical Diabetes 2003, 21: 91-92. DOI: 10.2337/diaclin.21.2.91.
- Wackers F, Young L, Inzucchi S, Chyun D, Davey J. Detection of ischemia in asymptomatic diabetics: Preliminary results of the DIAD study. Journal Of The American College Of Cardiology 2003, 41: 409. DOI: 10.1016/s0735-1097(03)81197-x.
- Novella S, Inzucchi S, Goldstein J. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle & Nerve 2001, 24: 1229-1231. PMID: 11494278, DOI: 10.1002/mus.1137.
- Nakchbandi I, Inzucchi S, Wirth J. Primary Pulmonary Hypertension and Thyroid Disease. CHEST Journal 2000, 118: 1224-1225. DOI: 10.1016/s0012-3692(15)37735-7.
Locations
1
Yale Endocrinology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 4th Floor Multispecialty Care Center
New Haven, CT 06511
1 of 4
- Yale EndocrinologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 4th Floor Multispecialty Care CenterNew Haven, CT 06511
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Diabetes CenterDana Clinic Building789 Howard Avenue, Ste 2nd FloorNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale Health Center55 Lock StreetNew Haven, CT 06511
1
Yale Endocrinology
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 4th Floor Multispecialty Care Center
New Haven, CT 06511
1 of 4
- Yale EndocrinologySmilow Cancer Hospital at Yale New Haven35 Park Street, Ste 4th Floor Multispecialty Care CenterNew Haven, CT 06511
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale Diabetes CenterDana Clinic Building789 Howard Avenue, Ste 2nd FloorNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale Health Center55 Lock StreetNew Haven, CT 06511